Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children

References

• Origa R. β-Thalassemia. Genet Med. 2017;19(6):609–619.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med. 2021;384(8):727–743.
   PubMed Web of Science ®Google Scholar
• Lee J-S, Cho SI, Park SS, Seong M-W. Molecular basis and diagnosis of thalassemia. Blood Res. 2021;56(S1):S39–S43.
   PubMed Web of Science ®Google Scholar
• Winichagoon P, Kumbunlue R, Sirankapracha P, et al. Discrimination of various thalassemia syndromes and iron deficiency and utilization of reticulocyte measurements in monitoring response to iron therapy. Blood Cells Mol Dis. 2015;54(4):336–341.
   PubMed Web of Science ®Google Scholar
• Langhi D Jr, Ubiali EM, Marques JF Jr, et al. Guidelines on beta-thalassemia major - regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associação Médica Brasileira - 2016. Rev Bras Hematol Hemoter. 2016;38(4):341–345.
   PubMedGoogle Scholar
• Cappellini MD, Cohen A, Eleftheriou A, et al. Iron overload. In: Cappellini MD, Cohen A, Porter J, et al. Editors. Guidelines for the Clinical Management of Thalassaemia, 2nd Revised ed. [Internet]. Nicosia (Cyprus): Thalassaemia International Federation, 2008.
   Google Scholar
• Porter J, Viprakasit V, et al. Iron overload and chelation. In: Cappellini MD, Cohen A, Porter J, Editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT), 3rd ed. [Internet]. Nicosia (CY): Thalassaemia International Federation; 2014.
   Google Scholar
• Susanah S, Idjradinata PS, Sari NM, et al. Time to start delivering iron chelation therapy in newly diagnosed severe β-thalassemia. Biomed Res Int. 2020;2020:1–6.
   Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood. 2011;118(4):884–893.
   PubMed Web of Science ®Google Scholar
• Porter JB, El-Alfy M, Viprakasit V, et al. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. Eur J Haematol. 2016;96(1):19–26.
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597–1602.
   PubMed Web of Science ®Google Scholar
• Ahmed J, Ahmad N, Jankharia B, et al. Effect of deferasirox chelation on liver iron and total body iron concentration. Indian J Pediatr. 2013;80(8):655–658.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang W, Huang L, et al. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One. 2013;8(12):e82662.
   PubMed Web of Science ®Google Scholar
• Sheth S. Iron chelation: an update. Curr Opin Hematol. 2014;21(3):179–185.
   PubMed Web of Science ®Google Scholar
• Di Maggio R, Maggio A. The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major. Br J Haematol. 2017;178(5):676–688.
   PubMed Web of Science ®Google Scholar
• Jahir SJ, Anwar S, Morshed AKMA, et al. Effect of deferiprone versus deferiprone with deferasirox in iron chelation therapy of thalassemia children. J Med Sci Clin Res. 2018;6(9):330–336.
   Google Scholar
• Colah R, Italia K, Gorakshakar A. Burden of thalassemia in India: the road map for control. Pediatr Hematol Oncol J. 2017;2(4):79–84.
   Google Scholar
• Petrou M. Screening for beta thalassaemia. Indian J Hum Genet. 2010;16(1):1–5.
   PubMedGoogle Scholar
• Thiyagarajan A. Advancement in thalassemia treatment: a view from gene therapy. Clin Pharmacol Biopharm. 2018;07 (01):e131.
   Google Scholar
• Verma IC, Saxena R, Kohli S. Present & future scenario of thalassaemic care & control in India. Indian J Med Res. 2011;134(4):507–521.
   PubMedGoogle Scholar
• Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187–189.
   PubMed Web of Science ®Google Scholar
• Lai Y-R, Liu R-R, Li C-F, et al. Efficacy of deferasirox for the treatment of iron overloads in Chinese thalassemia major patients: results from a prospective, open-label, multicentre clinical trial. Transfusion Med. 2013;23(6):389–396.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Hishikar R, Khandwal O, et al. Efficacy of deferasirox as an oral iron chelator in paediatric thalassaemia patients. J Clin Diagn Res. 2017;11(2):FC01–FC03.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin. 2009;33(sup1):S58–S569.
   PubMedGoogle Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583–1587.
   PubMed Web of Science ®Google Scholar
• Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458–465.
   PubMed Web of Science ®Google Scholar
• Peng C-T, Chow K-C, Chen J-H, et al. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan . Eur J Haematol. 2003;70(6):392–397.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364–2371.
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007;3:CD004839.
   Google Scholar